Mithra Announces Positive Donesta® Phase IIb Study Achieving Primary Objective and Confirming Promising Safety Profile

 

Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces positive topline results from the E4 Relief Phase II study of Donesta® for the treatment of Vasomotor Symptoms (VMS), and in particular hot flushes relief, in post-menopausal women, with the study achieving its primary and key secondary objectives. Donesta® is Mithra’s next-generation hormone therapy (HT) candidate with oral administration of Estetrol (E4).

Interested in a regular update of the Life Sciences and biotech sector in Flanders?